Redwood City-based OncoMed Pharmaceuticals has increased the number of shares it is offering its IPO, boosting the number of shares in its offering to 4.8 million shares. No other terms of the IPO have changed. OncoMed Pharmaceuticals develops therapeutics aimed at cancer stem cells. The company has filed to IPO on the Nasdaq as OMED. OncoMed filed for its IPO in May.